Cara Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Tvardi Therapeutics

15/05/2023 22:03

* Cara Therapeutics Inc  CARA.OQ  reported a quarterly
adjusted
loss of 49 cents​​ per share for the quarter ended in March. The
mean expectation of seven analysts for the quarter was for a
loss of 52 cents per share.
    * Revenue rose 28.7% to $6.17 million from a year ago;
analysts
expected $4.98 million. 
    * Cara Therapeutics Inc's reported EPS for the quarter was a
loss
of 49 cents​.
    * The mean earnings estimate of analysts had fallen by
about 117.3% in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Cara Therapeutics Inc shares had fallen by 18.5% this
quarter and lost 62.8% so far this year.
    * The company reported a quarterly loss of $26.67 million.
    * Wall Street's median 12-month price target for Cara
Therapeutics
Inc is $19.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
15 at 09:02 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.52          -0.49          Beat
 Dec. 31 2022      -0.32          -0.56          Missed
 Sep. 30 2022      -0.42          -0.43          Missed
 Jun. 30 2022      -0.25          -0.08          Beat